Search Bar & Filters
Found 40 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the long-term safety, tolerability, and effectiveness of the oral drug KT-621 in people with asthma who previously participated in a related KT-621 asthma study. This Phase 2b open-label extension study aims to understand how KT-621 behaves in the body over an extended period and whether it continues to help manage asthma symptoms. Participants receive KT-621 orally during the long-term extension phase, following their involvement in the parent study. The study monitors the drugs safety and efficacy over 52 weeks, focusing on treatment-emergent adverse events and changes in lung function and asthma control. Plasma levels of KT-621 are also measured throughout this period. During the study, participants will attend scheduled visits and complete laboratory tests, questionnaires, and an electronic diary to track their condition and treatment adherence. Researchers assess lung function through measurements like FEV1 and collect quality of life and asthma control data. Safety is closely monitored by recording adverse events, and the study spans up to one year of follow-up.
Actively Recruiting
Researchers are evaluating invobenitug, also known as procizumab, in people with cardiogenic shock CS, a serious condition where the heart cannot pump enough blood to vital organs. This Phase 1b2a trial aims to study the safety, tolerability, and early effectiveness of this monoclonal antibody, while also understanding how the drug behaves in the body. The study focuses on patients who have high levels of circulating dipeptidyl peptidase 3 cDPP3 and require ongoing support for blood pressure and heart function. Participants are randomly assigned to receive either invobenitug or a placebo. The dose of invobenitug is 10 mg per kg of body weight. The trial is designed as a multi-center, double-blind, placebo-controlled study to carefully compare the effects of the drug against placebo. Treatments are given under close medical supervision, with researchers monitoring how the drug affects cDPP3 levels and activity to help determine the best dose for future studies. Throughout the study, participants are closely observed for any adverse effects from the treatment for up to 30 days after receiving invobenitug. Researchers measure the number of treatment-related side effects and track how the drug is processed in the blood over time. They also assess changes in cDPP3 concentration and activity. The study collects detailed safety and laboratory data to understand how the drug works and to ensure participant safety during the trial period, which lasts until the last follow-up visit at around 30 days after treatment.
Actively Recruiting
This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.
Actively Recruiting
Researchers are evaluating how well a new injectable medicine called cagrilintide helps adults with excess body weight to lose weight. This phase 3 trial compares two different presentations of cagrilintide to placebo in people with overweight or obesity. The purpose is to understand the relative change in body weight from the start of treatment to the end of 26 weeks of treatment. Participants will be randomly assigned to one of three groups receiving weekly subcutaneous injections for 26 weeks one group receives cagrilintide with placebo matched to semaglutide in one device and placebo matched to cagrilintide in another another group receives cagrilintide in one device with matched placebos in the other and the last group receives matched placebos in both devices. This double-blind study uses devices for administration and treatment allocation is random. During the study, participants will have regular assessments including measurements of body weight and monitoring for adverse events from the start through 33 weeks. The main outcome measured is the relative change in body weight after 26 weeks of treatment. Safety is also monitored by counting any treatment-emergent adverse events or serious adverse events. Participants are involved for about 9 months in total.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Researchers are evaluating the efficacy and safety of combining ficlatuzumab with cetuximab compared to cetuximab alone in people with recurrent or metastatic RM HPV-negative head and neck squamous cell carcinoma HNSCC. This Phase 3, randomized, double-blind, placebo-controlled study focuses on participants who have not responded to prior anti-PD-1PD-L1 immune checkpoint inhibitors and platinum-based chemotherapy. The goal is to see if adding ficlatuzumab improves survival outcomes in this patient group. Participants are assigned to one of three groups two groups receive different doses of intravenous ficlatuzumab plus cetuximab on days 1 and 15 of each 28-day cycle, while the third group receives a placebo plus cetuximab on the same schedule. The study will enroll about 410 participants and compare progression-free survival and overall survival among these groups. Treatment cycles continue until disease progression or other study endpoints. During the study, participants will undergo regular imaging scans CT or MRI to assess tumor response every 8 weeks during the first year, then every 12 weeks in years 2 and 3, and every 6 months thereafter. Researchers will monitor safety, quality of life, and immune responses, including antidrug antibodies. The study period spans approximately 44 months with ongoing evaluations from randomization until death or last response assessment.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KT-621, an oral drug, in adults with uncontrolled moderate to severe eosinophilic asthma. This Phase 2b trial aims to understand how well KT-621 works, how safe and tolerable it is, and how the body processes the drug. Participants will be randomly assigned to one of four groups to receive either one of three doses of KT-621 or a matching placebo. Treatment will be given orally, and the study will track changes in lung function and asthma control over 12 weeks. Safety and drug levels in the blood will be monitored through 16 weeks. Throughout the study, participants will attend scheduled visits for lung function tests, asthma symptom questionnaires, and blood tests. Researchers will measure lung function improvement, asthma control, quality of life, treatment side effects, and drug concentration in plasma. The study will last until December 2027, with assessments focused on the 12 to 16-week treatment and monitoring periods.
Actively Recruiting
Researchers are studying telisotuzumab adizutecan, alone or combined with osimertinib, compared to standard care in adults with locally advanced or metastatic EGFR-mutated non-squamous non-small cell lung cancer NSCLC. The study aims to assess side effects and changes in disease activity over approximately 69 months, enrolling around 490 participants worldwide. This phase 23 open-label randomized trial evaluates treatment impact after progression on a third-generation EGFR tyrosine kinase inhibitor. In phase 2, participants receive one of two doses of telisotuzumab adizutecan through intravenous infusion either alone or with oral osimertinib. In phase 3, participants get the recommended phase 3 dose of telisotuzumab adizutecan or standard of care treatment. Treatments are allocated randomly, and the study includes multiple groups receiving different doses or combinations as part of the long study period. Participants will have regular visits at approved hospitals or clinics throughout the study. Researchers will monitor treatment effects through medical assessments, blood tests, questionnaires, and tracking side effects. Primary outcomes include objective response and progression-free survival assessed by independent review, while secondary outcomes measure overall survival, duration of response, disease control, and quality of life changes. The study carefully observes participants for up to approximately 69 months.
Actively Recruiting
Researchers are evaluating the safety of telisotuzumab vedotin in adults with previously treated non-squamous non-small cell lung cancer NSCLC that overexpresses the c-Met protein. This phase 2, open-label study aims to assess treatment-emergent adverse events, changes in disease activity, and how the drug behaves in the body. Approximately 150 participants will be enrolled worldwide and randomly assigned to one of three telisotuzumab vedotin dose groups. Participants will receive intravenous infusions of telisotuzumab vedotin at different doses as a monotherapy, administered over a three-year study period. The study compares three dosing regimens given by IV infusion, with participants assigned to one of three groups in a 111 ratio. Each participant will be treated and followed for up to three years to monitor safety and response. During the study, participants will attend regular visits at hospitals or clinics for medical assessments, blood tests, and monitoring of side effects. Questionnaires will be completed to report symptoms and quality of life. Researchers will track adverse events, including lung disease, neuropathy, and eye disorders, as well as treatment response and survival outcomes. The study includes ongoing safety monitoring and evaluation of drug levels in the blood throughout the treatment period.
1-10 of 40
1